Cargando…
Immunotherapy for malignant glioma
Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12–15 months. Moreover, conventional treatment, which includes surgery followed by radiation and chemotherapy, can...
Autores principales: | Suryadevara, Carter M., Verla, Terence, Sanchez-Perez, Luis, Reap, Elizabeth A., Choi, Bryan D., Fecci, Peter E., Sampson, John H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338494/ https://www.ncbi.nlm.nih.gov/pubmed/25722935 http://dx.doi.org/10.4103/2152-7806.151341 |
Ejemplares similares
-
Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy
por: Mangraviti, Antonella, et al.
Publicado: (2015) -
Bionanotechnology and the Future of Glioma
por: Chiarelli, Peter A., et al.
Publicado: (2015) -
Personalized Medicine for Gliomas
por: Ene, Chibawanye I., et al.
Publicado: (2015) -
Robotics in the neurosurgical treatment of glioma
por: Sutherland, Garnette R., et al.
Publicado: (2015) -
Convection-enhanced drug delivery for gliomas
por: Healy, Andrew T., et al.
Publicado: (2015)